Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDCC Regulatory News (DCC)

Share Price Information for DCC (DCC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5,850.00
Bid: 5,845.00
Ask: 5,855.00
Change: 0.00 (0.00%)
Spread: 10.00 (0.171%)
Open: 5,850.00
High: 5,875.00
Low: 5,830.00
Prev. Close: 5,850.00
DCC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DCC Healthcare acquires Ion Laboratories

12 Nov 2019 07:00

RNS Number : 0387T
DCC PLC
12 November 2019
 

 

 

12 November 2019

 

 

DCC Healthcare announces acquisition of Ion Laboratories

 

DCC plc, the leading international sales, marketing and support services group, announces that DCC Health & Beauty Solutions has acquired Ion Laboratories, Inc ('Ion'), a provider of contract manufacturing and related services to the growing health supplements and nutritional products market in the US.

 

The acquisition of Ion follows the acquisition of Elite One Source in February 2018 and will significantly enhance DCC Health & Beauty Solutions' service offering to customers in the US market. Ion has a broad product format capability encompassing tablets, capsules, powders and liquids across a variety of product categories including herbal and botanical products, probiotics and liquid nutritionals. Ion is currently commissioning a new nutritional gummies manufacturing line which will provide DCC Health & Beauty Solutions with capability in this fast growth category. Ion's customer base largely consists of specialty brand owners and its service offering includes product development, formulation, manufacturing, packaging and regulatory services.

 

Ion's well-invested facilities in Largo, Florida extend to 350,000 square feet and provide capacity to meet its organic growth plans. The facilities comply with FDA cGMP (current Good Manufacturing Practices) and Health Canada standards and are certified by leading third-party regulatory bodies, including NSF and USDA Organic. The business is led by an experienced management team, employs 360 people and has revenues of approximately $80 million.

 

The consideration was based on an enterprise value of approximately $60 million (£46 million), most of which was paid in cash on completion.

 

 

Donal Murphy, Chief Executive of DCC plc, said today:

 

"DCC Health & Beauty Solutions provides high-quality services to leading health and beauty brand owners, specialist retailers and direct sales organisations. The acquisition of Ion significantly enhances our presence in the US market and Ion will work closely with both Elite One Source and DCC Health & Beauty Solutions' European businesses to cross-sell the full breadth of the Group's comprehensive offering for health & beauty brands.

 

The US is the world's largest health supplements and nutritional products market. It is also an innovative, high-growth market, with a fragmented contract manufacturing base. We continue to be excited by the significant opportunities for organic and acquisitive growth in this market."

 

 

 

For reference:

Donal Murphy, Chief Executive

Conor Costigan, Managing Director, DCC Healthcare

Kevin Lucey, Head of Capital Markets

 

Telephone: +353 1 2799400

Email: investorrelations@dcc.ie

Web: www.dcc.ie

 

Powerscourt (Media)

Lisa Kavanagh / Victoria Palmer-Moore

Telephone: +44 20 7250 1446

Email: DCC@powerscourt-group.com

 

About DCC plc

DCC is a leading international sales, marketing and support services group with a clear focus on performance and growth. It operates through four divisions: LPG, Retail & Oil, Technology and Healthcare.

 

DCC is an ambitious and entrepreneurial business operating in 20 countries, supplying products and services used by millions of people every day. Building strong routes to market, driving for results, focusing on cash conversion and generating superior sustainable returns on capital employed enable the Group to reinvest in its business, creating value for its stakeholders.

 

Headquartered in Dublin, employing approximately 12,700 people, DCC's four divisions are:

·; DCC LPG - a leading LPG sales and marketing business with operations in Europe, the US and Asia and a developing business in the retailing of natural gas and electricity;

·; DCC Retail & Oil - a leader in the sales, marketing and retailing of transport fuels and commercial fuels, heating oils and related products and services in Europe;

·; DCC Technology - a leading route-to-market and supply chain partner for global technology brands and customers; and

·; DCC Healthcare - a leading healthcare business, providing products and services to healthcare providers and health and beauty brand owners.

 

DCC plc is listed on the London Stock Exchange and is a constituent of the FTSE 100. In its financial year ended 31 March 2019, DCC generated revenue of £15.2 billion and operating profit of £460 million.

 

DCC has an excellent record, delivering compound annual growth of 14% in operating profit and generating an average return on capital employed of approximately 19% over 25 years as a public company.

 

 

About DCC Healthcare

DCC Healthcare is a leading healthcare business, providing products and services to healthcare providers and health and beauty brand owners. DCC Healthcare operates through two businesses, DCC Vital and DCC Health & Beauty Solutions. DCC Vital markets and sells medical and pharmaceutical products to healthcare providers across all sectors of the healthcare market in the UK and Ireland. DCC Health & Beauty Solutions builds long-term partnerships with international brand owners, providing specialist services including product development, formulation, manufacturing and packaging.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ACQGGGQGGUPBGBG
Date   Source Headline
6th Mar 20244:52 pmRNSHolding in Company
28th Feb 20243:52 pmRNSTotal Voting Rights
7th Feb 20247:00 amRNSInterim Management Statement
31st Jan 20249:44 amRNSTotal Voting Rights
14th Dec 20237:00 amRNSBoard and Remuneration Committee Changes
30th Nov 202311:59 amRNSTotal Voting Rights
24th Nov 20235:34 pmRNSDirector/PDMR Shareholding
20th Nov 20235:45 pmRNSDirector/PDMR Shareholding
14th Nov 20237:01 amRNSAcquisition of Progas GmbH
14th Nov 20237:00 amRNSResults for the six months ended 30 September 2023
6th Sep 20237:00 amRNSDCC Energy Insights Day and Five New Acquisitions
31st Jul 20231:03 pmRNSTotal Voting Rights
13th Jul 20235:22 pmRNSResult of AGM
13th Jul 20237:00 amRNSAGM Trading Statement
14th Jun 202310:09 amRNS2023 Sustainability Report
14th Jun 202310:05 amRNS2023 Annual Report, Notice of AGM and Proxy Form
31st May 20234:38 pmRNSTotal Voting Rights
26th May 20234:58 pmRNSDirector/PDMR Shareholding
16th May 20237:00 amRNSResults for the year ended 31 March 2023
9th May 20237:00 amRNSStatement regarding Chief Executive
25th Apr 20237:00 amRNSNotice of Full Year 2023 Results
28th Feb 20239:36 amRNSTotal Voting Rights
8th Feb 20237:00 amRNSBoard Appointment
8th Feb 20237:00 amRNSInterim Management Statement
6th Jan 20235:39 pmRNSHolding in Company TR-1
30th Nov 20223:28 pmRNSTotal Voting Rights
14th Nov 20225:43 pmRNSDirector/PDMR Shareholding
8th Nov 20227:00 amRNSResults for the six months ended 30 September 2022
28th Oct 202212:20 pmRNSTotal Voting Rights
21st Oct 202212:19 pmRNSDirector Declaration
29th Sep 20227:16 amRNSDirector Declaration
27th Sep 20227:00 amRNSDCC acquires leading European solar distributor
16th Sep 20224:52 pmRNSHolding in Company TR-1
9th Sep 20225:10 pmRNSHolding in Company TR-1
8th Sep 20224:38 pmRNSHolding in Company TR-1
8th Sep 20227:00 amRNSDCC significantly expands in medical devices
7th Sep 20227:00 amRNSBoard Changes
16th Aug 20225:44 pmRNSHolding in Company TR-1
29th Jul 202211:02 amRNSTotal Voting Rights
26th Jul 20227:08 amRNSDirector Declaration
15th Jul 20223:52 pmRNSResult of AGM
15th Jul 20227:00 amRNSAGM Update
12th Jul 20227:00 amRNS2022 Sustainability Report
8th Jul 20226:11 pmRNSHolding in Company - TR1
30th Jun 20222:59 pmRNSAppointment of Chief Executive Officer, DCC Energy
16th Jun 202210:20 amRNS2022 Annual Report, Notice of AGM and Proxy Form
31st May 20221:19 pmRNSTotal Voting Rights
30th May 20229:00 amRNSDirector/PDMR Shareholding
26th May 20225:41 pmRNSDirector/PDMR Shareholding
17th May 20227:00 amRNSDCC plc Investor Event Today - Leading with Energy

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.